Following the measurement of IL-8 levels in patients with HNSCC under therapy with nivolumab, an anti-PD1 agent, treatment response rates were found to be higher in patients with significantly lower expression of IL-8 [18]. Here, CXCL8 is linked to head and neck squamous cell carcinoma.